IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
06 September 2023 - 9:00PM
IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage
biotechnology company focused on creating and developing engineered
IgM antibodies, today announced that Fred Schwarzer, Chief
Executive Officer, will participate in a fireside chat at the
Morgan Stanley 21st Annual Global Healthcare Conference on
Wednesday, September 13, 2023, at 9:30 a.m. EDT.
A live audio webcast of the event will be available on the
“Events and Presentations” page in the “Investors” section of the
Company’s website at
https://investor.igmbio.com/news-and-events/events-and-presentations.
A replay of the webcast will be archived on the Company’s website
for 90 days following the presentation.
About IGM Biosciences, Inc.IGM Biosciences is a
clinical-stage biotechnology company committed to developing and
delivering a new class of medicines to treat patients with cancer,
autoimmune and inflammatory diseases and infectious diseases. IGM’s
pipeline of clinical and preclinical assets is based on the IgM
antibody, which has 10 binding sites compared to conventional IgG
antibodies with only 2 binding sites. IGM also has an exclusive
worldwide collaboration agreement with Sanofi to create, develop,
manufacture, and commercialize IgM antibody agonists against
oncology and immunology and inflammation targets. For more
information, please visit www.igmbio.com.
Contact:Argot PartnersDavid
Pitts212-600-1902igmbio@argotpartners.com
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Jun 2024 to Jul 2024
IGM Biosciences (NASDAQ:IGMS)
Historical Stock Chart
From Jul 2023 to Jul 2024